Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants

L. van Oosten, J.J. Altenburg, Cyrielle Fougeroux, C. Geertsema, E.J. van den End, W.A.C. Evers, A.H. Westphal, S. Lindhoud, W.A.M. van den Berg, D.C. Swarts, L. Deurhof, Andreas Suhrbier, Thuy T. Le, S. Torres Morales, S.K. Myeni, Marjolein Kikkert, Adam F. Sander, Willem Adriaan de Jongh, Robert Dagil, Morten A. NielsenAli Salanti, Max Søgaard, T.M.P. Keijzer, D. Weijers, M.H.M. Eppink, R.H. Wijffels, M.M. van Oers, D.E. Martens, G.P. Pijlman^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

17 Citations (Scopus)

1 results

Finished
Prevent-nCoV: Prevention of SARS-CoV-2 infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine
1/04/20 → 30/06/22
Project: EU research project